tbuckley/cabot-search huggingface dataset:
Hypertensive Retinopathy Associated with Preeclampsia
Authors: Hanan Handor, Rajae Daoudi
Journal: New England Journal of Medicine (2014)

A 25-year-old primigravida at 36 weeks of gestation presented with a 2-week history of headache, light flashes, and blurred vision in both eyes. Her corrected visual acuity was 20/40 in the right eye and 20/50 in the left eye.
Association of Obesity with Asthma in Japanese Preschool Children
Authors: Y. Adachi, T. Itazawa, Y.S. Adachi, Y. Ito, Y. Okabe, K. Yoshida, Y. Ohya, H. Odajima, A. Akasawa, T. Miyawaki
Journal: Journal of Allergy and Clinical Immunology (2011)
Abstract 2196: Genome-wide analysis of DNA methylation patterns in formaldehyde-fixed paraffin-embedded (FFPE) human tumor specimens
Authors: Fabienne Brenet, Nicholas D. Socci, Daoqi You, Rafael Cabal, Marc Ladanyi, Agnes J. Viale, Joseph M. Scandura
Journal: Cancer Research (2010)

Abstract Formalin-fixed paraffin-embedded samples (FFPE) are in many case, the only available source of biological materiel available for translational studies. However the quantity and quality of nucleic acid extracted from FFPE samples is very often challenging (small amount and high level of degradation), which makes genomic analysis in general, and epigenomics analysis in particular, difficult to impossible. Here we are showing that we developed a robust, unbiased and cost effective method for genome-wide analysis of DNA methylation of FFPE DNA. Our method, named STAMP for Sequence Tag Analysis of Methylation Patterns, uses a recombinant protein containing a methyl-CpG binding domain (MBD) to precipitate methylated DNA fragments that are then identified by massively parallel sequencing using the SOLiD sequencer (ABI). We generate ∼15-million sequence tags per specimen and utilize an analytical platform comprised of custom-written R-language algorithms to study genomic DNA methylation patterns. We used this technology to compare the methylation patterns of matched fresh frozen (FF) and FFPE tumor specimens. Tissues had been stored for as long as 6 years. Because the STAMP method utilizes fragmented DNA as starting material we hypothesized that this method would be well-suited to the study of FFPE DNA methylation. Using this method, we found the methylation patterns of the FFPE and matched FF specimens were highly correlated. We successfully detected previously known methylated patterns and found hundreds of novel methylated regions. DNA methylation patterns were observed at all scales across the genome: from whole chromosomes to individual genes. We found that densely methylated elements are often highly conserved or closely associated with gene coding regions and promoters. We identified distinct patterns of DNA methylation surrounding the transcription start and termination sites of all genes. Genome-wide analyses of DNA methylation patterns of FFPE samples using the STAMP assay opens up the possibility to analyze large repositories of tumor specimens as well as samples that have been collected during routine clinical work and clinical trials. Large scales studies of DNA methylation using existing FFPE specimens linked to treatment outcomes may be rapidly translated to new epigenetic prognostic measures for cancer patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2196.
HOME BLOOD PRESSURE SIGNIFICANTLY DECREASES THROUGHOUT THE FIRST YEAR AFTER RENAL DENERVATION
Authors: Martine Beeftink, Willemien Verloop, Rosa L. de Jager, Margreet F. Sanders, Michiel Voskuil, Peter J. Blankestijn, Wilko Spiering
Journal: Journal of the American College of Cardiology (2015)
CASE REPORTS
Authors: ROBERT E. THOMAS
Journal: American Journal of Psychiatry (1955)

1. A case is reported of complete right hemiplegia following the first electroconvulsive treatment in a physically healthy 43-year-old man with a psychotic depression. 2. A brief review of 3 somewhat similar cases is reported from the literature. 3. A 16-month follow-up reveals the continued remission of the initial depression and partial recovery from the hemiplegia.
P5-15-03: Development of a Patient Decision Aid for Women 70 Years and Older with Stage I, Hormonally Sensitive, Breast Cancer Considering Adjuvant Treatment Post-Lumpectomy.
Authors: E Szumacher, J Wong, L D'Alimonte, J Angus, L Paszat, K Metcalfe, T Whelan, H Llewellyn-Thomas
Journal: Cancer Research (2011)

Abstract Background: Decision Aids (DA) are developed with the intent to support people in making specific and deliberate choices by improving information transfer about different outcomes. Previous research has shown that DAs can increase patient knowledge regarding treatment options, reduce decisional conflict, and increase patient satisfaction with the decision-making process. However, no DAs have been developed to help older breast cancer patients decide whether or not to undergo adjuvant RT. We developed and tested a DA for older women with stage I,ER/PR positive breast cancer considering adjuvant treatment post-lumpectomy and we examined its impact on treatment decision-making process. Methods and Materials: A DA was developed and evaluated in three steps following the Ottawa Decision Aid Framework: 1) Needs assessment (N=16); 2) Pilot I, to examine the DA's acceptability (N=12); and 3) Pilot II, a pre-test post-test (N=38) with older women with ER/PR responsive breast cancer post-lumpectomy who were receiving adjuvant RT. Measures included questionnaires to assess patient's satisfaction with the DA, patients’ self-reported decisional conflict (DC), level of distress, treatment-related knowledge, and choice predisposition Results: The DA is a booklet that details each adjuvant treatment option's benefits, risks and side-effects tailored to their clinical profile; includes a value clarification exercise; and steps to guide them towards their own treatment decision. All women felt the DA was helpful and informative. Compared with baseline scores, patients had a statistically significant (p &amp;lt; .05) reduction in DC (adjusted mean difference [AMD], −7.18; 95% confidence interval [CI], −13.50 to 12.59); increased clarity of the treatment benefits and risks (AMD, −10.86, CI, −20.33 to 21.49; and improved general treatment knowledge (AMD, 8.99, CI, 2.88 to 10.28) after using the DA. General trends were also reported in patient's choice predisposition scores suggesting potential differences in treatment decision after DA use. Discussion: This study provides evidence that this DA may be a helpful educational tool for this group of women. The quality of care for older breast cancer patients may be enhanced by using a tailored DA to help the patient be informed of their treatment options and to prepare for decision-making. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-15-03.
99mTc-MDP SPECT/CT Demonstrating Extraosseous Periarticular Amyloid Deposits in Primary Systemic Amyloidosis Associated With Multiple Myeloma
Authors: Krishan Kant Agarwal, Sellam Karunanithi, Shambo Guha Roy, Chandrasekhar Bal, Rakesh Kumar
Journal: Clinical Nuclear Medicine (2014)

Amyloidosis is a rare disorder characterized by variable extracellular accumulation of a complex substance consisting of proteinaceous fibrils (amyloid fibrils) and nonfibrillar glycoprotein or amyloid P component. We present a case of a primary systemic amyloidosis associated with multiple myeloma in a 48-year-old woman whose 99mTc-MDP SPECT/CT study revealed extraosseous periarticular uptake in amyloid deposits with no abnormal focal tracer uptake in the bone.
Running of the organ donor register could be privatised, says the Department of Health
Authors: H. Mooney
Journal: BMJ (2011)

Drug-induced kidney injury is a major clinical problem and causes drug attrition in the pharmaceutical industry. To better predict drug-induced kidney injury, kidney in vitro cultures with enhanced physiologic relevance are developed. To mimic the proximal tubule, the main site of adverse drug reactions in the kidney, human-derived renal proximal tubule epithelial cells (HRPTECs) were injected in one of the channels of dual-channel Nortis chips and perfused for 7 days. Tubes of HRPTECs demonstrated expression of tight junction protein 1 (zona occludens-1), lotus lectin, and primary cilia with localization at the apical membrane, indicating an intact proximal tubule brush border. Gene expression of cisplatin efflux transporters multidrug and toxin extrusion transporter (MATE) 1 (<i>SLC47A1</i>) and MATE2-k (<i>SLC47A2</i>) and megalin endocytosis receptor increased 19.9 ± 5.0–, 23.2 ± 8.4–, and 106 ± 33–fold, respectively, in chip cultures compared with 2-dimensional cultures. Moreover, organic cation transporter 2 (OCT2) (<i>SLC22A2</i>) was localized exclusively on the basolateral membrane. When infused from the basolateral compartment, cisplatin (25 µM, 72 hours) induced toxicity, which was evident as reduced cell number and reduced barrier integrity compared with vehicle-treated chip cultures. Coexposure with the OCT2 inhibitor cimetidine (1 mM) abolished cisplatin toxicity. In contrast, infusion of cisplatin from the apical compartment did not induce toxicity, which was in line with polarized localization of cisplatin uptake transport proteins, including OCT2. In conclusion, we developed a dual channel human kidney proximal tubule-on-a-chip with a polarized epithelium, restricting cisplatin sensitivity to the basolateral membrane and suggesting improved physiologic relevance over single-compartment models. Its implementation in drug discovery holds promise to improve future in vitro drug-induced kidney injury studies. <h3>SIGNIFICANCE STATEMENT</h3> Human-derived kidney proximal tubule cells retained characteristics of epithelial polarization in vitro when cultured in the kidney-on-a-chip, and the dual-channel construction allowed for drug exposure using the physiologically relevant compartment. Therefore, cell polarization–dependent cisplatin toxicity could be replicated for the first time in a kidney proximal tubule-on-a-chip. The use of this physiologically relevant model in drug discovery has potential to aid identification of safe novel drugs and contribute to reducing attrition rates due to drug-induced kidney injury.
AB0464 The Efficacy and Safety of Iguratimod in Rheumatoid Arthritis Patients with Chronic Renal Failure
Authors: K. Kume, K. Amano, S. Yamada, T. Kanazawa, K. Hatta
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Methotrexate (MTX) is the first line drug in rheumatoid arthritis (RA) patients. However MTX couldn9t be treated in RA patients due to renal failure. Iguratimod is a newly-developed disease-modifying antirheumatic drug (DMARD) that was approved in Japan in 2012. Iguratimod is not related with renal metastasis, and it is used for RA patients with chronic renal failure. <h3>Objectives</h3> To evaluate the efficacy and safety of Iguratimod in RA patients with chronic renal failure in a cohort study design. <h3>Methods</h3> RA patient (2010 ACR/EULAR criteria) with chronic renal failure (estimate GFR&lt;50) were eligible if they had active disease despite treatment. Consecutive 21 patients with moderate to severe active RA patients (DAS28&gt;3.2) were received Iguratimod plus previous DMARDs. Disease activity and renal function were assessed at baseline and 52 weeks follow-up. We compared disease activity and renal function at baseline with 52 weeks. <h3>Results</h3> 18 patients were completed this study. DAS 28 was significantly improved from baseline to 52 weeks (baseline: 5.33±1.44, 52 weeks: 3.45±1.65, p&lt;0.05). There were no patients that eGFR were worsened due to Iguratimod (baseline 65.4±12.2, 52 weeks 64.5±13.4, p=0.76). <h3>Conclusions</h3> Iguratimod was effective and safety in RA patients with chronic renal failure. Iguratimod could be used for RA patients with chronic renal failure. <h3>Acknowledgements</h3> We thank Dr Hiroshi Komori, Hiroyuki Ohta, and Naohiko Matsumoto at department of internal medicine, Hiroshima Clinic for checking data. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1040
Abstract 1517: Wnt signaling pathway seems a better target than k-ras pathway for colon cancer specific suicide gene therapy
Authors: Ladan Teimoori-Toolabi, Kayhan Azadmanesh, Sirous Zeianli, Ahmad Kaviani, Zahra Noorayee Kia, Leyli Ghaffarpoor, Manijeh Khandan
Journal: Cancer Research (2010)

Abstract As Wnt and K-ras are two most important signaling pathways activated in colon cancer, exploiting them for colon cancer specific gene therapy seems an attractive biological approach for therapy of colon cancer. Our aim was inserting specific promoters downstream to these pathways upstream of suicide genes. Therefore we investigated promoters downstream to these signaling pathways in order to insert them upstream of suicide genes. These promoters should be specifically upregulated by these pathways. They should have been proved to be inactive in normal cells of the body. These promoters should also be short enough to be inserted upstream of a therapeutic gene in a gene therapy construct. After investigating we found out Fibroblast Growth factor 18 (FGF18) and Urokinase Plasminogen Activator Receptor (UPAR) promoters which met the above mentioned criteria and seemed to be the most plausible promoters downstream to Wnt and K-ras signaling pathways. We inserted the most important parts of these promoters upstream of β-Gal as reporter and thymidine kinase as suicide genes. The activity of these promoters in two distinct colon cancer cell lines (HCT116 and SW480) and normal colon cells was studied. It was showed that FGF18 and UPAR promoter activity in HCT116 cell line was 0.25 and 0.187 times in comparison to CMV promoter while in SW480 this ratio was 0.09 and 0.02. Neither of promoters was active in normal colon cells. After applying the specific suicidal constructs in colon cancer cells, it was showed that both suicidal constructs reduced the viability of HCT116 in the presence of 20µg/ml of ganciclovir while in SW480 UPAR and FGF18 promoters reduced the viability in the presence of 40µg/ml and 20µg/ml ganciclovir respectively. The positive control suicidal construct induced significant reduction in the viability of both cell lines in the presence of 20µg/ml ganciclovir. The apoptosis induced by these suicidal constructs was also proved by M30cytodeath antibody in HCT116 and Annexin-PI in SW480. This difference in the method of proving apoptosis might be due to different mechanism of induced cell death by phosphorylated ganciclovir. These experiments showed that exploiting specific promoters downstream to activated signaling pathways in cancerous cells would be a good strategy for specific expression of therapeutic genes in cancerous cells. Also in colon cancer exploiting universal pathways such as wnt might be a better investment for this approach. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1517.
TEMPORAL RELATIONSHIP BETWEEN EPISODES OF ATRIAL FIBRILLATION AND INCIDENT STROKE IN PATIENTS WITH AN IMPLANTABLE CARDIAC DEVICE
Authors: Madhu Reddy, Moustapha Atoui, Rajarajeswari Swarna, Mamatha Vodapally, Maruthsakhi Molugu, Quratulain Javed, Anirudh Gone, Karthik Gangu, Ravali Neerumalla, Sudharani Bommana, Sandia Iskandar, Mohit Turagam, Madhav Lavu, Donita Atkins, Luigi Di Biase, Andrea Natale, Dhanunjaya Lakkireddy
Journal: Journal of the American College of Cardiology (2016)
FRI0503 Influence of Treatment on the Outcome of Polymyositis and Dermatomyositis
Authors: S. Gambini, L. Marinangeli, R. Morariu, A. Gabrielli, M.G. Danieli
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> To describe disease outcome and the influence of treatment modalities in a cohort of patients with polymyositis (PM) and dermatomyositis (DM) prospectively followed by our Internal Medicine Department, between 1985 and 2013. <h3>Methods</h3> We reviewed the medical notes of 91consecutive patients with PM and DM diagnosed according to the Bohan and Peter criteria. Since the diagnosis each patient have been followed by a standardised protocol. In March-May 2013 all of patients were enrolled in this study with the objective to evaluate a) the disease outcome b) disease activity, c) damage due to disease and treatment d) and the influence of treatment in outcome in the course of the disease. <h3>Results</h3> The series comprised 91 subjects with either PM (43) or DM (48) (Table 1). Myogenic abnormalities were detected by EMG in all of the cases, whereas muscle biopsy confirmed the diagnosis in 78% of the cases. All patients were treated with glucocorticoids. 72 patients (78%) received one (n=18) or more (n=31) agents, such as immunosuppressants, IVIg (in 39 patients), SCIg (n=18). Twenty-two patients (24%) (12F =55%; mean age 66 years) died after a mean follow-up of 91±84 months. According to the age-adjusted Cox regression model, male sex and a high MITAX value at the onset significantly correlate with mortality [HR =2.4, 95% CI =1.0 to 5.6 and HR =1.5 (95% CI =1.1 to 2.1), respectively]. Kaplan-Meyer estimates higher mortality for patients treated with corticosteroids or with corticosteroids and immunosuppressants as compared to patients treated with IVIG and/or SCIg (LR test p-value =0.3). Five-, 10- and 15-year survivals were higher in patients treated with immunoglobulin as compared with those treated with glucocorticoids or glucocorticoids plus immunosuppressants (p&lt;0.08,0.1 and 0.06,respectively). <h3>Conclusions</h3> PM and DM represent complex systemic disorders with a high rate of mortality. Patients initially treated with glucocorticoids and/or immunosuppressants had poorer outcome as compared with those treated with immunoglobulin (IV or SC). <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3245
Reverse Discordant Scintigraphy in Diffuse Goiter
Authors: A W Huiskes, J M De Klerk, P M Zelissen, P P Van Rijk, J W Van Isselt
Journal: Clinical Nuclear Medicine (1998)

Both Tc-99m pertechnetate and radioactive iodine (I-123 NaI or I-131 NaI) are useful in thyroid scintigraphy. These radiopharmaceuticals yield similar functional information in most patients. Occasionally, however, discordant results have been reported in the literature (warm or hot on the pertechnetate image and cold on the radioiodide image). Most of these reports have concerned the solitary thyroid nodule. A case is presented here with diffusely decreased Tc-99m pertechnetate uptake and normal I-131 NaI uptake in a patient with a diffuse goiter and subclinical hyperthyroidism, so-called reverse discordant behavior.
Prognostic relevance of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy – translational research program of the German SUCCESS-trial.
Authors: C Schindlbeck, B Rack, J Jueckstock, A Schneeweiss, E Thurner-Herrmanns, A Schneider, M Rezai, M Beckmann, K Pantel, W Lichtenegger, H Sommer, K Friese, W Janni, D Chatsiproios
Journal: Cancer Research (2009)

Abstract Abstract #303 Background:&amp;#x2028; The detection of Disseminated Tumor Cells in the Bone Marrow (BM) of Breast Cancer patients has shown prognostic significance in all stages of the disease. An alternative towards BM examination could be the analysis of peripheral blood for Circulating Tumor Cells (CTCs), which has demonstrated prognostic significance in metastatic disease. We analyzed peripheral blood samples from pts. Before and after adjuvant taxane-based chemotherapy as part of the translational research program of the German SUCCESS-trial.&amp;#x2028; Methods: Peripheral blood samples (23 ml each) from 1500 N+ and high risk N- breast cancer pts were analyzed for the presence of CTCs with the CellSearchSystem (Veridex, USA) before and after adjuvant chemotherapy. After automated immunomagnetic enrichment with an anti-Epcam-antibody, cells are labelled with anti-cytokeratin (8,18,19) and anti-CD45 antibodies to distinguish between epithelial cells and leukocytes. Samples are screened automatedly and positive events are visualised on a screen for re-evaluation.&amp;#x2028; Results: In143 pts (10 %) more than 1 CTC was detected before the start of systemic treatment (mean 14, range 2-827). 2 CTCs were found in 4 % of pts, 3 % had 3-5 CTCs and 1 % 6-10 and &amp;gt;10 CTCs, resp. The presence of CTCs did not correlate with tumor size (p=.32), grading (p=.36), hormonal status (p=.28) or Her2 status of the primary tumor (p=.82), but with the presence of lymph node metastases (p=.003). As negative control, three of 74 healthy individuals showed more than 1 CTC.&amp;#x2028; After completion of chemotherapy, 9 % of pts (n=130) presented with &amp;gt;1 CTC (mean 6, range 2-124). Of those initially CTC positive, 10% remained positive (n=15), whereas of those initially CTC negative, 8 % turned positive after chemotherapy (n=115, p=.42).&amp;#x2028; 21 recurrences have been reported during a median follow-up time of 12 months, and 7 pts have died of their disease. While detection of CTCs before systemic treatment did not show prognostic relevance for DFS (p=.89) and OAS (p=.71), presence of CTCs after chemotherapy was a significant predictor for both reduced DFS (p=.04) and OAS (p=.03).&amp;#x2028; Conclusions:&amp;#x2028; Our preliminary results demonstrate prognostic relevance of the presence of CTCs after adjuvant chemotherapy for the first time. Even in the adjuvant setting as well as during follow up, the examination of CTCs could be a valuable tool for monitoring the disease and the effectiveness of therapies. Longer follow-up of the SUCCESS-trial will have to be awaited to confirm these findings. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 303.